Head-to-head · WeighScore
BloomWell Rx vs Omada Health
The verdict
BloomWell Rx takes it — 61.3/100 to 55.6/100.
BloomWell Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. BloomWell Rx is a 100% online telehealth service offering personalized compounded GLP-1 weight loss — semaglutide (from $199/mo) and tirzepatide/GLP-1+GIP (from $249/mo) — after a free visit, plus wellness…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | BloomWell Rx | Omada Health |
|---|---|---|
| WeighScore | 61.3/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #296 | #435 |
| Semaglutide | $199/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | $249/mo (starting dose, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #296 · C
Strengths
- Transparent pricing — compounded semaglutide from $199/mo, tirzepatide (GLP-1/GIP) from $249/mo
- Free initial visit; fully online process with flexible dosing options
- Discloses meds are compounded by a licensed third-party pharmacy; also offers NAD+, sermorelin, glutathione
- Full legal suite published (Terms, Privacy, HIPAA Notice, Returns & Refunds)
Where it loses points
- 'Starts at' pricing — final cost depends on dose and plan
- Compounding pharmacy partner not named ('licensed third-party pharmacy')
- Not LegitScript-certified (no certification displayed)
- Operating medical entity not clearly named (site operated by a marketing agency)
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.